Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and the fifth most common tumor worldwide.
1,2 A limited panel of treatment options, which nowadays include tumor resection, liver transplantation, radiofrequency (thermal) ablation (RF(T)A), transarterial chemoembolization (TACE) and percutaneous ethanol injection (PEI), and the advanced stage at which the disease is generally diagnosed account for an overall 5-y survival rate of only 14%. 3, 4 With respect to systemic treatments, only the multi-targeted tyrosine kinase inhibitor sorafenib can moderately prolong the survival of patients with advanced HCC, but is accompanied by various side effects. 5 Due to the central role of the immune system in the pathogenesis of HCC, it appears indispensable to thoroughly decipher the immunological mechanisms that operate during the initiation and progression of liver cancer, as this might lead to the development of novel, innovative therapeutic strategies.
Chronic inflammatory disorders appear to increase the incidence of various types of cancer. [6] [7] [8] On one hand, malignant cells can activate an intracellular inflammatory program, such as that mediated by the transcription factor NFkB, which has a profound influence on oncogenesis and tumor progression by interfering with the control of cellular proliferation and cell death. 7 On the other hand, an inflammatory component is observed in the microenvironment of most neoplastic tissues independent of their relationship to an obvious inflammatory process. 6 The nature and localization of immune cells infiltrating the tumor or the surrounding stroma have an important impact on tumor progression. 2 Thus, while tumor infiltration by myeloid cells is often associated with poor prognosis, 9 the presence of T H 1 cells or cytotoxic T lymphocytes correlates with a reduced risk of relapse in several settings. 10 The close association between inflammation and cancer is particularly evident in the liver, because HCC almost exclusively arises upon chronic hepatic inflammation. 11 Nonetheless, a pro-inflammatory tumor microenvironment correlates with prolonged survival among HCC patients. 12 Thus, inflammation appears to act as a double-edged sword in hepatocarcinogenesis as it exerts pro-and antitumor effects, possibly explaining why antiinflammatory strategies have not yet entered the clinical practice for the treatment of hepatic neoplasms. A precise understanding of the molecular mechanisms linking hepatic inflammation with cancer as well as a detailed characterization of the functions of distinct immune cell subpopulations in the inflamed and neoplastic liver are urgently warranted. This review specifically focuses on the role of lymphocytes in liver cancer.
Inflammation Promotes Liver Cancer
In the large majority of the cases, HCC develops in the context of a persistently inflamed hepatic tissue, namely in patients with chronic hepatitis, fibrosis or cirrhosis. 3 Interestingly, virtually all the determinants of chronic liver inflammation, including hepatitis B or C virus (HBV or HCV, respectively) infections, obesity-associated non-alcoholic steatohepatitis (NASH) and alcoholism, dramatically increase the risk of developing HCC, corroborating the notion that inflammation itself rather than a specific carcinogenic factor promote a tumor-prone hepatic microenvironment. 11 Interestingly, independent studies from different geographical areas reported cases of HCC developing in the absence of concomitant cirrhotic alterations in the course of non-alcoholic fatty liver disease (NAFLD) and NASH. However, also in these settings local (NASH) or systemic inflammation (e.g., obesity, metabolic syndrome) was clearly related to an increased risk of HCC. [13] [14] [15] Conversely, the successful resolution of chronic inflammation, such as in the case of a permanent blockage of HBV replication or enduring HCV clearance, significantly reduces the risk for HCC. 16, 17 Chronic hepatic injury, impinging on cellular stress responses coupled to the death of hepatocytes, provokes an inflammatory ('wound-healing') response. Such a continuous cycle of cell death, compensatory proliferation and inflammatory signaling Hepatocellular carcinoma (HCC) typically occurs in patients with chronic inflammatory liver diseases, such as viral hepatitis or (non-)alcoholic steatohepatitis. Inflammation appears indeed as a crucial factor in hepatocarcinogenesis. Nevertheless, sophisticated animal models and studies of human samples revealed that the HCC also elicits antitumor immune responses. Patrolling and infiltrating lymphocytes (e.g., NKT and T cells, respectively) can exert decisive functions in the transition from chronic hepatic inflammation to cancer as well as in antitumor immune responses. an improved understanding of the cellular and molecular mechanisms whereby inflammation promotes or restricts hepatocarcinogenesis will open new avenues for therapeutic approaches to liver cancer.
is believed to facilitate genetic alterations and the expansion of transformed parenchymal liver cells. 7 Multiple studies of human specimens associated HCC with various genetic and epigenetic defects as well as with alterations in specific signal transduction cascades. 18 However, it often remains unclear whether these alterations are causative of HCC or represent a mere epiphenomenon of hepatocarcinogenesis. Animal models of HCC are a unique opportunity to analyze various aspects of the tumor biology, for example the genetics of oncogenesis and tumor progression, in vivo, as well as to investigate the role of inflammation in HCC. 19 Furthermore, animal models give the opportunity to evaluate therapeutic interventions for their ability to prevent HCC development and growth. Strikingly, the functional involvement of inflammation in hepatocarcinogenesis appears to be fundamentally different between the distinct mouse models of liver cancer that are commonly used to date.
The mouse models that are regularly employed in HCC research can be roughly subdivided into chemical-or oncogenedriven models, xenograft models and genetically-modified models ( Table 1) . 19 Several transgenic mouse models exist in which primary neoplastic lesions develop in the chronically inflamed liver, including the Mdr2 -/-, NEMO ΔLPC , Tak1 ΔLPC and AlbLTαβ mouse strains. In these models, oncogenesis proceeds along a sequence of liver inflammation, hepatic fibrosis and dysplasia, culminating in the appearance of bona fide carcinomas. For instance, the ablation of the multidrug resistance 2 (Mdr2, official name Abcb4) induces cholestatic hepatitis and HCC, which is promoted by NFκB signaling. 20 In the NEMO ΔLPC model, mice carry a hepatocyte-specific deletion of the gene coding for IκB kinase γ (IKKγ, best known as NEMO) and are therefore unable to activate NFκB in liver parenchymal cells, resulting in the development of steatohepatitis and HCC. 21 The liver-specific overexpression of lymphotoxin (LT) α and β induces hepatic inflammation and hepatitis. Hepatocarcinogenesis in this AlbLTαβ model shares some similarities with the development of HCC upon HBV or HCV infection, presumably because LTs and their receptor (LTβR) are upregulated in the course of viral hepatitis and consequent HCC. In this model, carcinogenesis is linked to the induction of the classical and alternative NFκB signaling pathways by the LTαβ-LTβR axis. 22 Altogether, these genetically modified mouse strains provided important insights into the hepatocarcinogenic functions of inflammation, notably into the tumor-promoting role of distinct lymphocyte subsets (see below). Conversely, these models might be less suitable to characterize the mechanisms of antitumor immunity triggered by HCC and how tumor-associated signals shape the immune response.
Primary Liver Cancer Provokes (Pro-and Antitumor) Immune Responses
Primary malignancies trigger an intrinsic inflammatory response that establishes a (pro-) tumorigenic microenvironment. 6 Specific oncogenes (for example, members of the RAS and MYC family) have been shown to induce a remodeling of the tumor microenvironment that results in the recruitment of leukocytes and lymphocytes, the expression of tumor-promoting cytokines and chemokines as well as the activation of neoangiogenesis. 23 Depending on their size, solid malignancies become depleted of oxygen and nutrients as they grow, resulting in the necrotic death of cancer cells coupled to the release of pro-inflammatory mediators. 24 The consequent inflammatory response not only stimulates neo-angiogenesis, but also recruits immune cells that can provide malignant cells with growth factors. 25 To analyze the immune response provoked by HCC in the liver, several mouse models have been developed ( Table 1 ). The administration of diethylnitrosamine (DEN) to mice at a very young age (12-14 d after birth) is the most widely used system to induce primary liver cancer. The carcinogenic activity of DEN relies on its ability to alkylate DNA. Several schedules for the administration of DEN to mice are known. In all cases, HCCs develop with a high incidence and in a highly reproducible fashion. 19 In this context, dysplastic lesions and tumors generally develop in otherwise non-inflamed liver tissue, therefore providing an excellent opportunity to study the immune response elicited by liver cancer. Several modifications of this model have been introduced, however, in which DEN-induced hepatocarcinogenesis and chronic liver injury (for instance, as induced by repetitive injections of carbon tetrachloride) are combined. This system is advantageous in that it allows for the study of the impact of hepatic inflammation on DEN-driven Abbreviations: DeN, diethylnitrosamine; eGF, epidermal growth factor; FGF19, fibroblast growth factor 19; TaK1, TGFβ-activated kinase 1; TGF, transforming growth factor. *rough classification with respect to the origin of the cancer-associated inflammatory response; **DeN can be combined with additional inflammatory stimuli such as chronic carbon tetrachloride (CCl4) injections in order to address the impact of an inflammatory microenvironment.
oncogenesis. 26 Alternative models of hepatocarcinogenesis proceeding in the absence of previous hepatic inflammation are provided by genetic defects resulting in the activation or overexpression of oncogenes (e.g., MYC, β catenin) or growth factors (e.g., transforming growth factor α, fibroblast growth factor 19). 19 
Antitumor Activity of Lymphocytes in Liver Cancer
The microenvironment of liver neoplasms typically contains various cell subsets of the innate immune system, like macrophages, neutrophils and natural killer (NK) cells, as well as T and B lymphocytes, central components of adaptive immunity. 2, 27 Tumor-infiltrating immune cells not only influence neoplastic cells, for instance as they interfere with their proliferative potential, or the local microenvironment, for instance as they stimulate angiogenesis or metastasis, but also interact with each other. 2 Tumor-associated macrophages (TAMs) and T cells are the immune cells most frequently found within HCCs. 27 Although TAMs comprise functionally diverse macrophage populations with pro-and antitumor activities, the overall effect of myeloid cells is likely to be pro-carcinogenic. Indeed, a population of immature myeloid cells best known as myeloidderived suppressor cells (MDSCs) is very efficient at suppressing local and systemic antitumor immune responses. 28 Lymphocytes, on the other hand, appear to exert important anticarcinogenic functions. Notably, a pro-inflammatory microenvironment seems to correlate with prolonged survival among HCC patients. 12 This effect has been linked to lymphocytes, since proinflammatory cytokines like tumor necrosis factor α (TNFα) or interferon γ (IFNγ) as well as Toll-like receptor 3 ligands stimulate the release of various chemokines, especially chemokine (C-C motif) ligand 2 (CCL2), CCL5 and chemokine (C-X-C motif) ligand 10 (CXCL10), in the tumor microenvironment. The expression levels of these cytokines correlate with the accumulation of T H 1 cells, CD8 + T lymphocytes and NK cells within neoplastic lesions, as well as with increased degrees of cancer cell death. 29 Accordingly, the activation of T and B cell-related signaling pathways, as documented by microarray analyses, was associated with improved survival among HCC patients. 27 Next, we will describe the putative functions of different lymphocyte subsets in the pathogenesis of liver cancer (summarized in Figure 1 and Table 2 ).
T and B Lymphocytes
The functional involvement of T and B lymphocytes, the main cellular effectors of adaptive immunity, has been investigated in mouse models of liver cancer. The administration of DEN to 14 d old mice results in the development of primary liver neoplasms after 42 weeks. In this model, T cells, especially cytotoxic CD8 + T cells, are significantly enriched in neoplastic livers. 27 Importantly, tumor progression, defined as both number of hepatic lesions and their size, is significantly enhanced in T and B cell-deficient Rag1 −/− mice. 27 The distinct role of T and B cells in hepatocarcinogenesis has been dissected by administering DEN to Igh6 −/− mice (so-called 'µMT mice', which only lack mature B cells), and MhcII −/− mice (that are characterized by the selective impairment of CD4 + T cells). In this setting, Igh6 −/− mice developed larger DEN-driven tumors than their wild-type counterparts, while MhcII −/− animals developed a slightly increased number of lesions. These data demonstrate an important role for B cells in limiting the growth In contrast to these findings, other mouse models revealed opposing functions for T and B cells in hepatocarcinogenesis. Activated T, B and NK cells are the main immune effectors expressing LTα and LTβ, which are members of the TNFα superfamily. 22 Upon binding to LTβR and TNFα receptor 1 (TNFR1), both of which are expressed by hepatocytes, LTs can activate the classical and alternative NFκB signaling pathway, which has an important role in HCC development. 30 The transgene-driven hepatocyte-specific overexpression of LTα and LTβ in mice (AlbLTαβ mice) results in chronic inflammation and liver cancer. 22 The role of lymphocytes in this model of hepatic carcinogenesis was investigated by crossing AlbLTαβ mice with Rag1 −/− mice. Strikingly, the absence of T and B cells (which characterizes Rag1 −/− mice) prevented hepatic carcinogenesis as driven by LT overexpression. 22 The completely contrasting results on the contribution of T and B cells to liver carcinogenesis as driven by DEN and LT overexpression perhaps reflects model-specific features that might allow for the elucidation of specific contributions of adaptive immunity to different aspects of hepatocarcinogenesis. DEN induces DNA alterations and malignant transformation very early after birth, and (pre)malignant cells appear to provoke an immune response whereby lymphocytes (at least attempt to) control oncogenesis. 27 Conversely, the overexpression of LTs activate NFkB signaling in hepatocytes, resulting in the secretion of inflammatory chemokines. These chemokines recruit lymphocytes that perpetuate an aggressive chronic hepatitis, constituting a prerequisite for tissue remodeling, hepatocyte proliferation and ultimately malignant transformation. 22 While these studies highlighted the prominent cytotoxic functions of adaptive immune effectors, either on hepatocytes (inducing chronic hepatitis) or on (pre)malignant cells (controlling oncogenesis and tumor progression), more recent works described a "sensing" function for T cells in identifying pre-malignant hepatocytes and mediating their eradication (Fig. 2) . Upon the activation of oncogenes, cells can enter a permanent cell cycle arrest that is generally referred to as cellular senescence. Recent findings indicate that the immunosurveillance of senescent hepatocytes limits the development of hepatocellular cancer. 31 As a consequence of the hydrodynamic injection of plasmids coding for oncogenic Nras
G12V
, murine hepatocytes enter senescence in vivo, hence stimulating the development of primary liver tumors. Senescent (Nras G12V -expressing) hepatocytes were found to secrete various cytokines and chemokines that attract multiple subsets of immune cells. Among these, CD4
+ T H 1 cells were identified to trigger the clearance of senescent hepatocytes, a process that relied on freshly replenished macrophages . 31 In view of the long-standing controversy on the role of T cell-dependent immunosurveillance, these data suggest that cellular senescence might be necessary for the elicitation of a CD4 + T-cell response against pre-cancerous cells. 31, 32 A recent study lent further support to this hypothesis by showing that the combined activity of IFNγ and TNFα released by T H 1 cells induces a permanent growth arrest in cancer cells. 33 
NKT Cells
Natural killer T (NKT) cells are a subpopulation of T lymphocytes that share phenotypic and functional characteristics with NK cells. Most murine NKT cells express an invariant Vα14Jα18 T-cell receptor (TCR) and recognize glycolipids presented by the non-polymorphic MHC-like molecule CD1d. These classical NKT cells are called invariant NKT (iNKT) cells, to distinguish them from other rare NKT-cell subtypes that upregulate NK-cell markers upon stimulation. 34 The liver is the organ with the highest number of NKT cells, both in absolute terms and compared with other T-cell subpopulations. Indeed, NKT cells constitute about 30% of all lymphocytes in the liver. 35 NKT cells can rapidly produce T H 1 (e.g., IFNγ and TNFα) or T H 2 (e.g., IL-4 and IL-13) cytokines upon stimulation. We have recently demonstrated that iNKT cells, which are abundantly patrolling the liver in steady-state conditions, employ chemokine (C-X-C motif) receptor 6 (CXCR6) to accumulate in the liver as a very early response to experimental hepatic injury. CXCR6-dependent iNKT cells provide essential pro-inflammatory signals that activate local macrophages and perpetuate inflammation. 36 NKT cells may also exert important functions in antitumor immunity. For instance, an antimetastatic effect of NKT cells stimulated with IL-12 in vivo has been reported in several studies based on distinct cancer cells. 37, 38 While NKT lymphocytes appear to directly mediate antimetastatic effects upon IL-12 stimulation, they might activate other effector cells, such as NK cells, by releasing IFNγ in response to α-galactosylceramide (α-GalCer). 39 Even in absence of exogenous stimulation, the production of IFNγ by NKT cells appears essential for preventing the development of methylcholanthrene (MCA)-driven sarcomas in mice. 40 Interestingly, iNKT cells from cancer patients have been shown to produce reduced amounts of IFNγ than iNKT cells from healthy subjects, pointing to an important role for iNKT cells in oncogenesis and tumor progression. 41 Although NKT cells are predominant in the liver, relatively few data exist on their specific functions in hepatocarcinogenesis. In the course of β catenin-driven hepatocarcinogenesis, NKT cells constitute a key component of hepatic inflammatory responses. In line with this notion, the ablation of iNKT cells accelerates the progression of β catenin-induced liver tumors. 42 These findings suggest that iNKT cells may be promising targets for anticancer immunotherapy. However, especially in the context of HCC, the precise function of NKT cells remains poorly understood.
NK Cells
NK cells are also enriched among hepatic lymphocytes and seem to play an important role in liver tumorigenesis. NK cells can be activated by NKT cells, dendritic cells and Kupffer cells upon the release of IFNγ and IL-12. Conversely, regulatory T cells (Treg) and hepatic stellate cells are able to inhibit NK cell functions by secreting IL-10 and TGFβ. 43 The main functions of NK cells in the liver are to eliminate infected cells, malignant cells and stressed hepatocytes or to act as regulatory cells on other immune cells by producing cytokines. Thus, the cytolytic activity of NK cells seems to be important to control (pre)malignant cells in the liver. 43, 44 Accordingly, the intrahepatic levels of proliferating immune cells, predominantly T cells and CD56 + NK cells, have been found to correlate not only with the survival of HCC patients but also with the degree of cancer cell death. 12 Furthermore, HCC patients show significantly reduced levels of CD56 dim NK cells in neoplastic lesions as compared with neighboring normal tissues, and these tumor-infiltrating NK cells produce limited amounts of IFNγ and exert minimal cytotoxicity. 45 The study of human specimens and mouse models of HCC provided further insights into the antineoplastic activity of NK cells in precancerous fibrotic and cirrhotic livers. Fibrosis limits the activation of NK cells, perhaps separating them from targets like (pre)malignant cells, which in part explains the link between fibrotic liver microenvironment and the increased propensity of developing hepatic tumors. 46, 47 Moreover, the phagocytosis of NK cells by hepatic stellate cells as well as alteration in the pattern of expression of NK cell-activating ligands have been observed in the context of cirrhosis and HCC. 48, 49 These data imply that NK-cell functions are important to prevent HCC, and hence often impaired as hepatic tumorigenesis proceeds. 
Immunosuppression and Tumor Escape
Despite the antitumor activity of lymphocytes described above, the immune system oftentimes fails to control hepatic carcinogenesis. Indeed, some mechanisms of immunosuppression have been identified to support the development and progression of HCC. One of them consists in the selection of specific cancer cells that are able to escape immunosurveillance, a process commonly described as immunoediting. Through immunoediting, the tumor acquires the capacity to survive in spite of an intact immune system. 50 The downregulation of FAS and the IFNγ receptor, which are necessary for cytotoxic functions of CD8 + T cells, on hepatic cancer cells support this hypothesis. 51, 52 HCCs and their microenvironment can also influence the cytotoxic functions of CD8 + T cells. Inhibitory receptors are generally upregulated on tumor-associated antigen (TAA)-specific T cells. 53 Increased levels of programmed cell death 1 (PDCD1, best known as PD-1), which is frequently expressed on activated T cells, have been observed on the surface of HCC-infiltrating lymphocytes. 54 This is known to result in decreased expression of CD3ξ and CD28, which are critical for CD8 + T-cell activation. 55 In addition, the priming of T cells in the liver might be impaired in the course of HCC progression. Indeed, HCC lesions have been shown to contain reduced amounts of CD4 + T cells. This may relate to an impaired functionality of dendritic cells (DCs), which have been described to produce limited amounts of IL-12 in this context. 56 In any case, reduced levels of CD4 + T cells may also result in the impaired activation of cytotoxic CD8 + T cells. 57, 58 Different cells like MDSCs and Kupffer cells are known to exert immunosuppressive effects and hence may contribute to HCC progression. 28 For example, hepatic macrophages can express high levels of inhibitory molecules such as PD-1 ligand 1 (PD-L1), which limits the effector functions of PD-1-expressing CD8 + T cells, 59 or secrete immunosuppressive cytokines like IL-10. 60, 61 Among lymphocytes, Tregs have been shown to suppress antitumor immunity by inhibiting both CD8 + T and NK cells. 62 Tregs are enriched within HCCs, presumably owing to the local upregulation of CCL20 and the consequent recruitment of Tregs via CCR6. 63, 64 High levels of tumor-infiltrating Tregs correlate with poor prognosis in HCC patients. 64, 65 The effector functions of NK cells, which can be suppressed by Tregs and MDSC, are also dependent on the expression of specific markers on the surface of neoplastic cells, including the NK cell-activating factor MHC class I-related chain A (MICA). 66 Changes in MICA expression levels, for example as observed in the course of HCV infection, were found to correlate with hepatocarcinogenesis.
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Impact of Immunotherapy on HCC
Considering the important role played by the immune system in the liver, notably during the development and progression of HCCs, boosting immune effector functions such as those mediated by NK or CD8 + T cells stands out as a promising treatment option for HCC patients. 68 One approach that has been followed to this aim was the administration of vaccine targeting the α-fetoprotein (AFP), which is expressed to high levels by many HCCs. However, short-term immune responses elicited by vaccination did not translate into a clinical benefit. 69, 70 Similarly, with the aim to stimulate CD8 + and CD4 + T cells with a broad antigenic panel, dendritic cells were pulsed with lysates from a hepatoblastoma cell line and then infused to HCC patients. In a pilot study, this approach led to disease stabilization or partial responses in 28% of patients. 71 The injection of dendritic cells pulsed with autologous cancer cell lysates even increased the 1-y survival rate among patients with advanced HCCs. About 13% of these patients displayed indeed a partial response and 50% stable disease. 72 Ongoing research aims at discovering the TAAs that may allow for the generation of optimal antitumor CD8 + and CD4 + T-cell responses. A different immunotherapeutic strategy against HCC would be to support antitumor T-cell responses by counteracting immunosuppressive cell subsets like Tregs or MDSCs. In studies investigating the effects of Treg depletion by suitable antibodies or cyclophosphamide, an induction of AFP-specific CD4 + T-cell responses was observed. 73 The rather unspecific stimulation of the immune system via cytokines was also investigated as an immunotherapeutic approach to HCC by several groups. In a small trial, the injection of IL-2 and IFNγ in combination with transarterial chemotherapy was shown to lead to tumor regression in 70% of patients. 74 Immunotherapeutic approaches directly targeting NK and NKT cells are rare at the moment, although both cell types have been shown to exert a significant influence on tumor development and progression in murine models of HCC. 42, 43 However, the activity of these cells may very well be modulated by several (effective) chemotherapeutics, including the multi-tyrosine kinase inhibitor sorafenib, which is the systemic drug most widely used for the palliative treatment of HCC patients to date. 75 By blocking different tyrosine kinases, sorafenib inhibits the proliferation and survival of cancer cells and mediates antiangiogenic effects. 76 A recent study demonstrated that sorafenib also influences the immune system, as it might promote an NFκB-dependent switch from immunosuppressive to immunostimulatory TAMs, eventually resulting in NK-cell activation.
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Conclusions
The immune system and especially lymphocytes play a key role in the development and progression of hepatocellular carcinoma. On one hand, lymphocytes represent an important component of the inflammatory microenvironment favoring the initiation and progression of malignancies in the context of chronic liver disease. On the other hand, lymphocytes are key effectors of antitumor immune responses, for instance as they sense senescent cells (CD4 + T lymphocytes), as they release cytokines and stimulate other immune cells (NKT cells) or as they exert direct cytolytic activities against transformed cells (NK and CD8 + T lymphocytes). However, many mechanisms are in place that simultaneously suppress antitumor immunity. An improved understanding of the molecular and cellular cascades whereby inflammation promotes or restricts hepatocarcinogenesis will open novel avenues for the treatment of liver cancer.
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